Download
13019_2024_Article_2903.pdf 2,12MB
WeightNameValue
1000 Titel
  • Impact of minimal invasive extracorporeal circulation on systemic inflammatory response – a randomized trial
1000 Autor/in
  1. Halle, Deborah Richards |
  2. Benhassen, Leila Louise |
  3. Søberg, Karsten Lund |
  4. Nielsen, Peter Fast |
  5. Kimose, Hans-Henrik |
  6. Bauer, Adrian |
  7. Hasenkam, John Michael |
  8. Modrau, Ivy Susanne |
1000 Verlag
  • BioMed Central
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-07-03
1000 Erschienen in
1000 Quellenangabe
  • 19(1):418
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13019-024-02903-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221091/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Extracorporeal circulation causes a systemic inflammatory response, that may cause postoperative haemodynamic instability and end-organ dysfunction. This study aimed to investigate the impact of minimal invasive extracorporeal circulation (MiECC) on the systemic inflammatory response compared with conventional extracorporeal circulation (CECC).</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Patients undergoing coronary artery bypass grafting were randomized to MiECC (<jats:italic>n</jats:italic> = 30) and CECC (<jats:italic>n</jats:italic> = 30). Primary endpoint was tumor necrosis factor-α. Secondary endpoints were other biochemical markers of inflammation (IL1β, IL6 and IL8, C-reactive protein, leukocytes), and markers of inadequate tissue perfusion and tissue damage (lactate dehydrogenase, lactate and creatine kinase-MB). In addition, we registered signs of systemic inflammatory response syndrome, haemodynamic instability, atrial fibrillation, respiratory dysfunction, and infection.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Patients treated with MiECC showed significantly lower levels of tumor necrosis factor-α than CECC during and early after extracorporeal circulation (median: MiECC 3.4 pg/mL; CI 2.2–4.5 vs. CECC 4.6 pg/mL; CI 3.4–5.6; <jats:italic>p</jats:italic> = 0.01). Lower levels of creatine kinase-MB and lactate dehydrogenase suggested less tissue damage. However, we detected no other significant differences in any other markers of inflammation, tissue damage or in any of the clinical outcomes.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Lower levels of TNF-α after MiECC compared with CECC may reflect reduced inflammatory response, although other biochemical markers of inflammation were comparable. Our results suggest better end-organ protection with MiECC compared with CECC. Clinical parameters related to systemic inflammatory response were comparable in this study.</jats:p> </jats:sec><jats:sec> <jats:title>Clinical registration number</jats:title> <jats:p>NCT03216720.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Female [MeSH]
lokal Coronary Artery Bypass/adverse effects [MeSH]
lokal Aged [MeSH]
lokal Biomarkers/blood [MeSH]
lokal Humans [MeSH]
lokal Middle Aged [MeSH]
lokal Tumor Necrosis Factor-alpha/blood [MeSH]
lokal Coronary artery bypass grafting
lokal Systemic Inflammatory Response Syndrome/blood [MeSH]
lokal Systemic Inflammatory Response Syndrome/etiology [MeSH]
lokal Male [MeSH]
lokal Research
lokal Postoperative Complications/blood [MeSH]
lokal Systemic inflammatory response syndrome
lokal Systemic inflammatory response
lokal Coronary Artery Bypass/methods [MeSH]
lokal Extracorporeal Circulation/methods [MeSH]
lokal Minimal invasive extracorporeal circulation
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SGFsbGUsIERlYm9yYWggUmljaGFyZHM=|https://orcid.org/0000-0003-1298-0299|https://frl.publisso.de/adhoc/uri/U8O4YmVyZywgS2Fyc3RlbiBMdW5k|https://frl.publisso.de/adhoc/uri/TmllbHNlbiwgUGV0ZXIgRmFzdA==|https://frl.publisso.de/adhoc/uri/S2ltb3NlLCBIYW5zLUhlbnJpaw==|https://frl.publisso.de/adhoc/uri/QmF1ZXIsIEFkcmlhbg==|https://frl.publisso.de/adhoc/uri/SGFzZW5rYW0sIEpvaG4gTWljaGFlbA==|https://frl.publisso.de/adhoc/uri/TW9kcmF1LCBJdnkgU3VzYW5uZQ==
1000 Hinweis
  • DeepGreen-ID: db66f4af0d454ea7b2c0235ac873bb47 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Medtronic External Research Program |
  2. NIH/NCRR Colorado CTSI |
  3. Health Research Foundation of Central Denmark Region |
1000 Fördernummer
  1. -
  2. -
  3. -
1000 Förderprogramm
  1. -
  2. -
  3. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Medtronic External Research Program |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer NIH/NCRR Colorado CTSI |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Health Research Foundation of Central Denmark Region |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6523504.rdf
1000 Erstellt am 2025-07-06T22:03:39.664+0200
1000 Erstellt von 322
1000 beschreibt frl:6523504
1000 Zuletzt bearbeitet 2025-07-29T20:26:07.610+0200
1000 Objekt bearb. Tue Jul 29 20:26:07 CEST 2025
1000 Vgl. frl:6523504
1000 Oai Id
  1. oai:frl.publisso.de:frl:6523504 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source